Buscar
Mostrando ítems 1-6 de 6
Serum Potassium Dynamics During Acute Heart Failure Hospitalization
(Springer, 2020-10-17)
[Abstract]
Background.
Available information about prognostic implications of potassium levels alteration in the setting of acute heart failure (AHF) is scarce.
Objectives.
We aim to describe the prevalence of ...
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC‐HF Baseline Characteristics and Comparison With Contemporary Clinical Trials
(Willey Online Library, 2020-09-20)
[Abstract]
Aims
The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ...
Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data From 9222 Chronic Heart Failure Patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry
(Willey Online Library, 2020-04-03)
[Abstract]
Aims.
We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all‐cause or cardiovascular death ...
International Consortium for Health Outcomes Measurement (ICHOM): standardized patient-centered outcomes measurement set for heart failure patients
(American College of Cardiology Foundation, 2020-03)
[Abstract] Whereas multiple national, international, and trial registries for heart failure have been created, international standards for clinical assessment and outcome measurement do not currently exist. The working ...
Hyperkalemia in Heart Failure Patients in Spain and Its Impact on Guidelines and Recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry
(Elsevier, 2020-04)
[Abstract] Introduction and objectives: Hyperkalemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction because it limits the use of effective drugs. We report estimates of ...